About GT20029's Efficacy and Strength
    Chat 3/18/2023

    At a glance
    In this general discussion post, the primary subjects mentioned are
    💧 GT20029 (topical) once a week
    the tone is 😐 neutral.

    Other terms

    The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
    View this post in the Community →

    Similar Community Posts Join

    5 / 218 results

      community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance

      in Research/Science  123 upvotes 11 months ago
      The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 7 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Kintor’s GT20029 Phase 1 success

      in Update  73 upvotes 1 year ago
      Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

    Related Research

    5 / 5 results